Graftys SA

Graftys SA focuses on developing and manufacturing synthetic calcium phosphate bone graft substitutes for orthopedics and sports medicine, providing innovative solutions for patients with bony defects. Founded in 2005 and headquartered in France, Graftys SA specializes in synthetic bone graft substitutes. The company has raised EUR 2. 00 mn in its latest funding round in July 2022.

Graftys has completed 8 deals to date and has not undergone any major business pivots or restructuring. The founder's prior experience includes significant involvement in the medical sector, though specific details about previous companies are not provided. Graftys specializes in the development, manufacturing, and commercialization of synthetic calcium phosphate bone graft substitutes, which are innovative solutions for orthopedics, spine, and sports medicine. Their products are designed to address bony voids or defects that do not compromise the stability of the skeletal structure and are delivered using a unique double-compartment mixing syringe.

These products have been registered in over 30 countries, including important markets in Europe and the United States, targeting healthcare professionals involved in trauma and reconstructive surgeries. In the most recent fiscal year 2021, Graftys reported a revenue of EUR 1,938,779. 20 and an EBITDA of EUR 101,228. 30.

The company's business-to-business (B2B) model generates revenue through multi-year supply agreements, including a renewed collaboration with Arthrex for synthetic bone graft materials, with offerings supplied in diverse packaging options. Following the EUR 2 million funding raised on July 18, 2022, Graftys plans to utilize this capital to launch new products and expedite the commercialization of its current offerings. The company is exploring expansion into additional geographic markets, which will be detailed as plans progress. Specific product launches and timelines for market entry will be communicated as they become available.